The Food and Drug Administration (FDA) announced on Tuesday that it will be hosting a public meeting in November to discuss gender and sex differences in the effects of CBD and other cannabinoids.

In a notice set to be published in the Federal Register on Wednesday, FDA’s Office of Women’s Health announced the event, emphasizing that as interest in CBD and other derivatives of marijuana and hemp continues to grow, there’s a need to explore the science of these cannabinoids in the context of gender and sex. That’s particularly true when it comes to cannabis use among pregnant women, the agency said. Read the full story HERE